Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05841628 · ClinicalTrials.gov registry record · NA
Tolerability of 532 nm Laser Treatment of Port Wine Stains
A NA study of Port-Wine Stain, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05841628: Recruiting NA study of Port-Wine Stain, sponsored by Massachusetts General Hospital.
NCT05841628 is a NA study of Port-Wine Stain that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05841628, a NA study of Port-Wine Stain, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn about treatment of port wine birthmarks treated with an FDA-approved 532 nm laser. The main questions it aims to answer are: * How well are the treatments tolerated? * Are there differences in tolerability of the treatment when a single high fluence laser pulse is used (the standard treatment) versus using multiple low fluence pulses? * Are there differences in results when using a single high fluence pulse versus multiple low fluence pulses? type of study: Clinical Trial Participants will undergo 3 monthly laser treatments with the 532 nm DermaV laser. Part of their birthmark will be treated with the standard single-pulse high fluence approach, and other parts will be treated with the multiple-pulse low fluence approach.
Primary Outcome
For each treatment area within the port wine stain, a blinded investigator will assess improvement (0 - 25%, 26 - 50%, 51 - 75%, 76 - 100%)
Conditions Studied
Interventions
- DEVICE 532 nm laser treatment
Study Locations (1)
Massachusetts
- Wellman Center for Photomedicine, Harvard Medical School - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT05841628 shows while recruiting
NCT05841628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Port-Wine Stain appearing as the primary indexed condition, and to 1 intervention - of which 532 nm laser treatment is the first listed.
NCT05841628 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05841628 about?
NCT05841628 is a clinical study titled "Tolerability of 532 nm Laser Treatment of Port Wine Stains". The goal of this study is to learn about treatment of port wine birthmarks treated with an FDA-approved 532 nm laser. The main questions it aims to answer are: * How well are the treatments tolerated? * Are there differences in tolerability of the treatment when a single high fluence laser pulse i...
What is the current status of trial NCT05841628?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2023-05-01. Estimated completion is 2026-12.
What conditions does trial NCT05841628 study?
This clinical trial studies the following conditions: Port-Wine Stain.
What interventions are being tested in trial NCT05841628?
The interventions under investigation include: 532 nm laser treatment (DEVICE).
Who is sponsoring clinical trial NCT05841628?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05841628 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Port-Wine Stain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05841628's enrollment target sits among peer trials
15 1882nd of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI